Jan 7, 2020 update
WHO statement: COVID-19: a challenging start to 2021, new COVID-19 variants and promising vaccine progress – Be it vaccine allocation and prioritization, access to medical supplies and tests, or public health measures and policies to control the pandemic, we have a responsibility to base decisions on the core values that are at the heart of humanity: solidarity, equity and social justice. It is the only way out of these uncertain times, because no one is safe until everyone is safe.
Jan 6, 2020 update
European Commission: Authorisation of a second safe and effective vaccine against COVID-19 – The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Moderna, the second COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency and is endorsed by the Member States.
EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU – The European Medicines Agency has recommended granting a conditional marketing authorisation for COVID-19 Vaccine Moderna to prevent Coronavirus disease (COVID-19) in people from 18 years of age. This is the second COVID-19 vaccine that EMA has recommended for authorisation.
Dec 22, 2020 update
European Commission: Recommendation on EU coordinated approach to travel and transport in response to new variant of coronavirus in the UK – Following the rapid increase of COVID-19 cases in parts of England, of which a large proportion belongs to a new variant of the virus, the Commission today adopted a Recommendation on a coordinated approach to travel and transport measures.
Dec 21, 2020 update
European Commission: Authorisation of the first safe and effective vaccine against COVID-19 – The European Commission has granted a conditional marketing authorisation for the COVID‑19 vaccine developed by BioNTech and Pfizer, making it the first COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency and is endorsed by the Member States.
EMA: Recommendation on a first COVID-19 vaccine for authorisation in the EU – EMA has recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age. EMA’s scientific opinion paves the way for the first marketing authorisation of a COVID-19 vaccine in the EU by the European Commission, with all the safeguards, controls and obligations this entails.
EMA opinion on Comirnaty – COVID-19 mRNA vaccine – Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older. Comirnaty contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. Comirnaty does not contain the virus itself and cannot cause COVID-19.
ECDC: First COVID-19 vaccine authorised for use in the EU – ECDC welcomes the authorisation of the first vaccine against COVID-19 in EU/EEA. We have been looking forward to this moment for a long time.
Dec 7, 2020 update
JRC: New reference materials for the quality control of SARS-CoV-2 antibody tests – The new reference materials can be used to check the correct functioning of SARS-CoV-2 antibody tests. They can also support research on immunity against COVID-19 and help monitor the efficiency of experimental vaccines.
Dec 3, 2020 update
European Commission: “Staying safe from COVID-19 during winter” strategy – The strategy recommends continued vigilance and caution throughout the winter period and into 2021 when the roll out of safe and effective vaccines will occur. The Commission will then provide further guidance on a gradual and coordinated lifting of containment measures.
WHO: Latest update on the pandemic and preparations for COVID-19 vaccine deployment – The virus still has the potential to do enormous damage unless we do everything in our power to stop its spread. And part of the solution will be vaccination.
Nov 25, 2020 update
European Commission: Contract with Moderna to ensure access to a potential vaccine – The European Commission approved a sixth contract under the EU Vaccines Strategy, this time with the pharmaceutical company Moderna. The contract provides for the initial purchase of 80 million doses on behalf of all EU Member States, plus an option to request up to a further 80 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.
Nov 18, 2020 update
Nov 11, 2020 update
European Commission: Contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine – the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
Oct 8, 2020 update
European Commission: Fighting COVID-19 disinformation Monitoring Programme – A further set of reports provided by the signatories of the Code of Practice on Disinformation as part of the COVID-19 monitoring and reporting programme is published.”
European Commission: third contract to ensure access to a potential vaccine – The European Commission approved a third contract with a pharmaceutical company, Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
European Commission: A joint procurement contract with Gilead for the supply of Remdesivir – The Commission has signed a joint procurement framework contract with the pharmaceutical company Gilead for the supply of up to 500,000 treatment courses of Veklury, the brand name for Remdesivir, and the opportunity to increase supply beyond the 500,000 treatment courses.
Sept 23, 2020 update
ECDC: New COVID-19 situation dashboard – The ECDC COVID-19 situation dashboard, first launched in March 2020, has been improved with a simplified design and enhanced functionality enabling users to easily monitor the COVID-19 pandemic at the European and global level.
July 23, 2020 update
EP: EU long-term budget deal must be improved for Parliament to accept it – The recovery fund is a “historic move”, but long-term EU priorities such as the Green Deal and the Digital Agenda are put at risk. say MEPS in a resolution on the conclusions of the extraordinary European Council meeting of 17-21 July 2020.
EU budget: the recovery fund is a “historic move”, but long-term EU priorities such as the Green Deal and the Digital Agenda are put at risk, say MEPs. Press release → https://t.co/kypXv5Yz5T pic.twitter.com/UPX7SMfR67
— European Parliament (@Europarl_EN) July 23, 2020
July 22, 2020 update
UNAIDS: New COVID-19 Law Lab to provide vital legal information and support for the global COVID-19 response – The COVID-19 Law Lab initiative gathers and shares legal documents from over 190 countries across the world to help states establish and implement strong legal frameworks to manage the pandemic. The goal is to ensure that laws protect the health and wellbeing of individuals and communities and that they adhere to international human rights standards.
European Commission: Strengthening health and other key services in Tajikistan with €112 million – As part of its Team Europe Global Response, the European Commission announced €112.2 million to strengthen health, education and social services in Tajikistan and support the country in its coronavirus response.
European Commission: EU supports vaccine research with additional €100 million – The Commission will co-fund with €100 million a call launched by the Coalition for Epidemic Preparedness Innovations (CEPI) to support the rapid development of coronavirus vaccines.
We need efficient treatments and vaccines to eliminate the danger of the #coronavirus.
That is why we support @CEPIvaccines in its endeavour to rapidly develop the most promising vaccine candidates → https://t.co/2AuK1kyhwL pic.twitter.com/KWk7CmBQ03
— European Commission 🇪🇺 (@EU_Commission) July 22, 2020
July 21, 2020 update
EMA: Infrastructure for real-world monitoring of treatments and vaccines – EMA has now set up an infrastructure to support the monitoring of the efficacy and safety of COVID-19 treatments and vaccines when used in day-to-day clinical practice.
July 20, 2020 update
EU Commissioner Reynders answering MEP’s question on Voluntary’ coronavirus quarantine apps
1. Does the Commission agree that an application tracking the movements of individuals as an alternative to a 14-day stay in a state quarantine centre cannot be considered ‘voluntary’?
2. Does the Commission consider the mandatory choice between a 14-day stay in a state quarantine centre or the use of a surveillance application using highly sensitive data to be in line with the Charter of Fundamental Rights?
3. What action will the Commission take against Member States deploying such allegedly ‘voluntary’ applications?
EP Policy Department study: Assessment of COVID-19 surveillance case definitions and data reporting in the EU – The COVID-19 crisis has revealed shortcomings in the area of public health data comparability that can have a serious impact on the coordination of the EU response. It is fundamental to ensure consistency of definitions across Member States of ‘possible’ and ‘probable’ cases, or of ‘death due to COVID-19’, in order to provide the necessary comparability to evaluate the public health response, the stress on the health system and the impact on the population’s health.
July 17, 2020 update
EPRS paper: Coronavirus: An uncertain future – This note offers links to recent commentaries and reports from international think tanks on coronavirus and related issues.
European Commission Short-term EU health preparedness for COVID-19 outbreaks – This Communication aims at ensuring the EU’s short-term health preparedness in case of further COVID-19 outbreaks in Europe. It draws particular attention to the need to reduce the burden of the 2020/2021 seasonal flu, so to mitigate the additional strain on health systems should this coincide with a further outbreak of COVID-19.
European Commission: EU programme promotes digital solutions to the crisis in Africa – The European Union has announced a €10.4 million programme to promote digital solutions to fight the coronavirus pandemic and to improve the resilience of health and education systems in the Democratic Republic of Congo, Rwanda and Burundi.
July 16, 2020 update
EPRS paper: Coronavirus restrictions – The role of therapeutics, testing, and contact-tracing – This publication provides an overview of the role of therapeutics, testing and contact-tracing apps in the context of lifting coronavirus-related restrictions on movement and social life in EU Mss.
EU Commissioner Breton answering MEP’s question on Fake news and disinformation during the COVID-19 crisis
1. Is the Commission considering introducing greater control and monitoring procedures with regard to the current recommendations?
2. Is the Commission planning to introduce new and tougher legislation to fight against disinformation?
EU Commissioner Kyriakides answering MEP’s question on Coronavirus outbreak
1. Does it agree that there is a need to establish a single prevention protocol for all Member States and, at the same time, a communication task force to provide European citizens with accurate information, shield them from dangerous myths about the disease, and make them aware of the necessary precautionary measures?
2. In order to counter the spread of fake or misleading news about the situation in each Member State, can it provide, as a matter of extreme urgency, details of the preventive measures taken by each Member State, and statistics on the number of tests each has carried out, the results and confirmed deaths?
EU Commissioner Lenarčič answering MEP’s question on Extraordinary measures to address the consequences of COVID-19
1. How does the Commission intend to improve the coordination of crisis management mechanisms among the Member States?
2. As existing EU funds will not be sufficient to deal with the outcomes of the pandemic, does the Commission plan to use all the margins available under the multiannual financial framework to mitigate the negative impact of the crisis in the EU?
3. Taking into account the urgent need to make progress with research in diagnostics, vaccines, and therapeutics — indispensable for mitigating the COVID-19 pandemic — can the Commission confirm that it intends to bolster investments in research and innovation outside the framework of the Horizon 2020 Programme?
July 15, 2020 update
EU Council: Regulation on Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease
July 7, 2020 update
The first EU-ASEAN webinar dedicated to High-Performance Computing (HPC) COVID19-related modelling and diagnostic took place on 10 July 2020. As a collaborative initiative among the ASEAN-HPC Task Force, the ASEAN Committee for Science Technology and Innovation (COSTI), the ASEAN Secretariat Science & Technology Division (ASEC S&T), and the Enhanced Regional EU-ASEAN Dialogue Instrument (E-READI), the webinar brought together speakers and representatives from the EU and ASEAN MSs scientific organizations and academia.
July 3, 2020 update
Does the Commission plan to present new legislation in this area, particularly on EU patent protection, patent sharing and accessibility?
Does the Commission plan to propose that Member States engage the debate on patent protection for COVID-19 treatments and vaccines in the WTO, and particularly within the TRIPs framework?
Once a vaccine is found, what steps will the Commission take to ensure that it is made available and accessible to low and middle income countries as soon as possible?